Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085885" target="_blank" >RIV/00023001:_____/25:00085885 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/25:10503231 RIV/00064203:_____/25:10503231
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0006295225006288?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0006295225006288?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.bcp.2025.117363" target="_blank" >10.1016/j.bcp.2025.117363</a>
Alternative languages
Result language
angličtina
Original language name
Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure
Original language description
Heart failure (HF) is a life-threatening disease characterized by substantial morbidity and mortality. Yet despite recent advances, prognosis remains poor. Cyclic guanosine 3 ',5 '-monophosphate (cGMP) mediates a wide range of physiological processes in various cell types. Its deficiency has been implicated in numerous pathological cardiovascular diseases, including HF, pulmonary hypertension (PH), and kidney disease. Therefore, restoring and enhancing the nitric oxide (NO)-soluble guanylyl cyclase (sGC)-cGMP signalling pathway appears to have far-reaching therapeutic potential. The discovery of sGC stimulators and activators marked a milestone in the field of NO-sGC-cGMP pharmacology, enabling NO-independent and long-acting enhancement of cGMP signalling without the formation of NO-derived radicals. Over a decade ago, the sGC stimulator riociguat was approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH). More recently, the sGC stimulator vericiguat was approved for symptomatic chronic HF. A number of sGC activators are currently being investigated for the treatment of chronic kidney diseases. This review summarizes the evidence for NO-sGC-cGMP signalling in the regulation of cardiovascular and cardiac function, focusing on preclinical and clinical evidence for sGC stimulators and sGC activators in HF subtypes. Promising results have been observed in clinical trials of HF with reduced ejection fraction (HFrEF),
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biochemical pharmacology
ISSN
0006-2952
e-ISSN
1873-2968
Volume of the periodical
242
Issue of the periodical within the volume
December 2025 (Part 3)
Country of publishing house
GB - UNITED KINGDOM
Number of pages
17
Pages from-to
"art.no. 117363"
UT code for WoS article
001586015900003
EID of the result in the Scopus database
2-s2.0-105020616435